Navigation Links
WaferGen to Present at the Cambridge Health Institute's Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference
Date:3/19/2008

Chief Scientific Officer Dr. David Gelfand to Deliver Keynote Speech

FREMONT, Calif., March 19 /PRNewswire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC Bulletin Board: WGBS), a leading developer of state-of-the-art gene expression, genotyping, cell biology and stem cell research systems, today announced that David Gelfand, Ph.D., chief scientific officer, will deliver a keynote speech at the Cambridge Healthtech Institute's Fifth Annual Molecular Diagnostics Partnerships in Personalized Medicine Conference. The conference will be held March 26-28, 2008, at the Moscone North Convention Center in San Francisco, California.

Dr. Gelfand's speech, which will take place at 8:35 a.m. (PST) on Friday, March 28, will celebrate the 25th anniversary of polymerase chain reaction (PCR) and discuss the future of revolutionary technology. He is widely considered one of the world's foremost experts on PCR and DNA sequencing and is credited as the inventor of Thermus aquaticus (Taq) DNA Polymerase for use in PCR.

During his speech, Dr. Gelfand will highlight the key role that PCR has played in the success of the life science industry since its invention, particularly its contribution to the advent of the field of molecular diagnostics. He will also discuss the key advances in PCR over the past 25 years and outline future innovations that will be required for the realization of the technology's ultimate potential. Finally, Dr. Gelfand will provide an overview of WaferGen's SmartChip(TM) Real-Time PCR System, the world's first whole genome, high throughput gene expression real-time PCR platform.

About the SmartChip(TM) Real-Time PCR System

The SmartChip Real-Time PCR System(TM) is designed as the first whole genome, high throughput gene expression real-time PCR platform and promises to deliver significant speed and cost advantages to researchers in the gene expression and genotyping markets. It is estimated that the genetic analysis market alo
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WaferGen to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
3. WaferGen Announces Management Team Promotions
4. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
5. Avicena Group to Present at Noble Financial Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. CEL-SCI to Present at the Noble Financial Conference
10. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., BOCARATON,Fla.,Nov.25/PRNewswire/--Formanybusi....Thenation,slargestandfastestgrowingnetworkofexper...vised bioidenticalhormones has grownthenumberof ...o36physicians -andisinprogresstoaddmorephysician-o...syear. ,, Inthepastyear ,BodyLogicMDhasopened13...
(Date:11/25/2009)...EGO,Nov.25/PRNewswire-FirstCall/--ArdeaBiosciences...,Pharm.D.,presidentandchiefexecutiveofficer,willpr...ce. , ,Presentationdetailsareasfollows:,PiperJaf...cember1,2009,Time:2:00p.m.EasternTime,Location:The...://www.corporate-ir.net/ireye/,target=,_blank,tit...
(Date:11/24/2009)... The New York investment bank KTA Capi...has agreed an AU$6.7 mil convertible note private ...private placement was arranged by KTA Capital as N... New York (PRWEB) November ...nk KTA Capital, LLC ("KTA Capital") has ...
(Date:11/24/2009)...UIS,Nov.24/PRNewswire-FirstCall/--Sigma-AldrichCor...OMXconferenceonTuesday,December1stat1:45PMGMTinLon...audiobroadcastovertheInternetavailableat http://i...ickthe"Webcast"icontoaccessthisfile. ,, About...andHighTechnologycompany.Itschemicalandbiochemical...
Breaking Biology Technology:Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 2Nation's Largest Network of Doctors Specializing in Bioidentical Hormones Grows at an Exponential Rate 3Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference 2KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2
...and product pipeline, BOTHELL, WA and VANCOUVER, ...euticals, Inc. (NASDAQ: OGXI ), a biopharmaceutic...cialization of new therapies that address,unmet ne...udited financial,results for the third quarter and...rter 2008 Financial Results, On August 21, 2008, ...
...hua-PRNewswire/ -- Simcere Pharmaceutical,Group (N...f branded generic,pharmaceuticals and innovative a...China market, announced today its participation in... 2008. The conference will be held at,the Mandarin...cere,s chief financial officer, Frank Zhigang Zhao...
...0 InspireMD, developers of,the novel MGuard(TM) c...TM),was successfully implanted in a complex lesion...erformed by Dr. Dariusz Dudek and was broadcast,fr...fast Meeting Symposium,"A New Approach to Treating...as met with great enthusiasm and excitement. Some ...
Other Biology Technology:OncoGenex Reports Third Quarter Financial Results 2OncoGenex Reports Third Quarter Financial Results 3OncoGenex Reports Third Quarter Financial Results 4OncoGenex Reports Third Quarter Financial Results 5OncoGenex Reports Third Quarter Financial Results 6OncoGenex Reports Third Quarter Financial Results 7OncoGenex Reports Third Quarter Financial Results 8OncoGenex Reports Third Quarter Financial Results 9Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 2MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 3MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008 4
(Date:11/25/2009)...he course of a lifetime, the heart pumps some 250 ...rder to do this, the muscle fibers of the heart ha...ded by Dr. Wolfgang Rottbauer, vice chair of the D... Hospital (Chairman: Prof. Dr. H. A. Katus), has d...ability of the smallest muscular unit, the sarcome...
(Date:11/24/2009)...ousands of years it has been prescribed by traditi...s from headaches and stomach pain to fever and flu...tle University have been able to scientifically pr...ta otherwise known as Brazilian mint. , Testing...m led by researcher Graciela Rocha was able to sho...
(Date:11/24/2009)...ists have crystallised a protein that may help gut...protein could be used by probiotic producers to id...it to people. , "Probiotics need to interact with... and if they attach to surfaces in the gut they ar... their activity," says Dr Nathalie Juge from the I...
Breaking Biology News(10 mins):New genetic cause of cardiac failure discovered 2Got a pain? -- Have a cup of Brazilian mint 2A sticky solution for identifying effective probiotics 2New PICC Mimics Nature 50488 1New PICC Mimics Nature 50488 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 1Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 2Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 3Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 4Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 5Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 6Stemedica Discovers Significant Breakthrough in the Use of Stem Cells and Stem Cell Factors for the Treatment of Retinal Degeneration 50484 7Press Ganey Launches Community Image Solution 50480 1Press Ganey Launches Community Image Solution 50480 2Press Ganey Launches Community Image Solution 50480 3
.... , Infectious proteins known as prions have bee...E). The culprits are "incorrectly folded" proteins... bases for such prion diseases are not yet fully u...others are not? A team headed by Beat Meier (ETH Z...f Bordeaux, France) has examined two different for...
... Montreal, 13 June 2008 Researchers at the McG...sity and the University of British Columbia (UBC) ... cause an increase in serious adverse events, but ...s adverse events. , Several drugs containing com...noids, are available for medical purposes in Canad...
... discovered that a protein previously shown to hav...he formation of cysts in Autosomal Dominant Polycy...n life-threatening genetic diseases and has shown...isease in mice. , The discovery was published ...ine yesterday. , The team showed that a pro-in...
Other Biology News:Tracking prions 2Medicines derived from cannabis: a review of adverse events 2Rong Li Lab identifies new role of inflammatory protein in PKD and a possible treatment 2
...neral description: Dish uses include large-scale c...s, hybridizations. Compatible with PBA Flexys TM ... CLS number is a new product number, created to ea...availability yet, please order under the old Sigma...
Mouse Anti-beta II Tubulin Monoclonal Antibody, Unconjugated, Clone 7B9 from Abcam
Mouse Anti-Desmoplakin I & II Monoclonal Antibody, Unconjugated, Clone DP2.15 from Meridian Life Science, Inc.
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes from BD Biosciences - Discovery Labware
Biology Products: